Primary Care Today

Part 2: Are You Ready for Biosimilars? What the Oncology Team Should Know

Host: Matt Birnholz, MD

Guest: Gary Cohen, MD

Biosimilars undergo a rigorous evaluation process to ensure high quality and no clinically meaningful difference between biosimilars and the reference product. To learn more about how biosimilar clinical trials are designed to confirm biosimilarity, tune in to the second episode of this two-part series featuring Dr. Gary Cohen, Associate Professor of Oncology at John’s Hopkins School of Medicine and Emeritus Director of the Sandra and Malcolm Berman Cancer Institute at GBMC.

©2020 Amgen Inc. All rights reserved. USA-CBU-80729 10/20

Podden och tillhörande omslagsbild på den här sidan tillhör ReachMD. Innehållet i podden är skapat av ReachMD och inte av, eller tillsammans med, Poddtoppen.